Company: Dr. Reddy's Laboratories Ltd. Category: Company News


The revenues from India during the Q4 was at ₹650 crore.For FY19, PAT stood at ₹1,880 crore while revenue was 15,385 crore
May 17, 2019, 7:40 p.m.
Publisher: livemint.com

Divestment of derma assets, lower operating costs helped firm post higher profit growth during the quarter
May 17, 2019, 7:26 p.m.

Dr Reddy’s Laboratories Ltd reported that its consolidated net profit increased by 44 per cent at Rs 434 crore in the fourth quarter ended March 31,
May 17, 2019, 4:15 p.m.

Revenue for the quarter under discussion was up by 14 per cent at Rs 4,016.60 crore against Rs 3,534.90 crore in the same quarter last fiscal
May 17, 2019, 3:42 p.m.


Revenue for the quarter under discussion was up by 14 per cent at Rs 4,016.60 crore against Rs 3,534.90 crore in the same quarter last fiscal
May 17, 2019, 3:42 p.m.

The Cubicin for Injection (daptomycin for injection) brand and generic had US sales of ~$640.8mn MAT for the most recent twelve months ending in March 2019, according to IQVIA Health.
May 15, 2019, 12:40 p.m.

As per IQVIA Health data, the AndroGel (testosterone gel) brand and generic had US sales of ~$815.6mn MAT for the most recent twelve months ending in February 2019.
May 6, 2019, 2:52 p.m.

According to information posted on the US Food and Drug Administration(USFDA), the company initiated a voluntary recall of Divalproex 100-count and 500-count bottles, totaling 33,958 bottles on April
April 26, 2019, 2:12 p.m.

The company has received approval for the product Clopidogrel in China.
April 25, 2019, 3:21 p.m.

Sources said the company got approval earlier this month for generic Clopidogrel, which is used primarily to prevent blood clotting and acts against cardiovascular problems
April 23, 2019, 9:22 p.m.

-->